Skip to main content

Advertisement

SpringerLink
Log in

Vaccination against hepatitis a in patients with chronic liver disease

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with underlying chronic liver disease. HAV vaccination is effective and safe, although the vaccine is less immunogenic in patients with advanced liver disease. Despite recommendations to immunize patients with chronic liver disease, rates of HAV vaccination remain low, thus highlighting the need for public health programs to increase awareness about HAV vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Centers for Disease Control and Prevention: Disease burden from hepatitis A, B, and C in the United States. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/ dz_burden02.htm. Accessed December 13, 2005.

  2. Berge JJ, Drennan DP, Jacobs RJ, et al.: The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000, 31:469–473.

    Article  PubMed  CAS  Google Scholar 

  3. Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996, 45:1–30. [Published erratum appears in MMWR Morb Mortal Wkly Rep 1997, 46:588.]

    Google Scholar 

  4. National Institutes of Health: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 2002, 36(5 Suppl 1):S3-S20.

    Article  Google Scholar 

  5. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171.

    Article  PubMed  Google Scholar 

  6. Bell BP, Kruszon-Moran D, Shapiro CN, et al.: Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 2005, 23:5798–5806.

    Article  PubMed  Google Scholar 

  7. Saab S, Lee C, Shpaner A, Ibrahim AB: Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005, 12:101–105. This study evaluated the prevalence of HAV seropositivity among 473 patients with various causes of chronic liver disease. Overall, the seroprevalence of HAV was 55%; multivariable analysis identified older age, Hispanic or Asian race, and alcohol use as independent predictors of prior exposure to HAV.

    Article  PubMed  CAS  Google Scholar 

  8. Manfredi R, Calza L, Chiodo F: Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. Clin Microbiol Infect 2005, 11:845–848.

    Article  PubMed  CAS  Google Scholar 

  9. Ochnio JJ, Patrick D, Ho M, et al.: Past infection with hepatitis A virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs. CMAJ 2001, 165:293–297.

    PubMed  CAS  Google Scholar 

  10. Villano SA, Nelson KE, Vlahov D, et al.: Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997, 25:726–728.

    PubMed  CAS  Google Scholar 

  11. Siddiqui F, Mutchnick M, Kinzie J, et al.: Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001, 96:858–863.

    Article  PubMed  CAS  Google Scholar 

  12. Shim M, Khaykis I, Park J, Bini EJ: Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005, 42:688–695. This large retrospective cohort study highlights the need for public health programs to increase awareness of the importance of HAV vaccination in patients with chronic liver disease.

    Article  PubMed  Google Scholar 

  13. Kiefer LA, Honish A, Predy G, Talbot JA: The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000, 162:207–208.

    PubMed  CAS  Google Scholar 

  14. Lugoboni F, Quaglio G, Pajusco B, et al.: Prevalence of hepatitis A among drug users in north-eastern Italy. Is vaccination necessary in low prevalence areas? Eur J Public Health 2005, 15:464–466.

    Article  PubMed  Google Scholar 

  15. Acharya SK, Batra Y, Bhatkal B, et al.: Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. J Gastroenterol Hepatol 2003, 18:822–827.

    Article  PubMed  Google Scholar 

  16. Spada E, Genovese D, Tosti ME, et al.: An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol 2005, 43:958–964.

    Article  PubMed  Google Scholar 

  17. Hadler SC: Global impact of hepatitis A infection: changing patterns. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis H. Baltimore: Williams & Wilkins; 1991:14–20.

    Google Scholar 

  18. Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290. This frequently cited prospective cohort study in Italy demonstrated that the case fatality rate was 35% in patients with chronic HCV infection who developed HAV superinfection.

    Article  PubMed  CAS  Google Scholar 

  19. Mele A, Tosti ME, Stroffolini T: Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:1771–1773.

    Article  PubMed  CAS  Google Scholar 

  20. Helbling B, Renner EL, Kammerlander R: Acute hepatitis A in patients with chronic hepatitis C [letter]. Ann Intern Med 1999, 131:314.

    PubMed  CAS  Google Scholar 

  21. Yao G: Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis H. Baltimore: Williams & Wilkins; 1991:76–78.

    Google Scholar 

  22. Keeffe EB: Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995, 90:201–205.

    PubMed  CAS  Google Scholar 

  23. Keeffe EB, Iwarson S, McMahon BJ, et al.: Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998, 27:881–886. This multicenter study evaluated the efficacy and safety of HAV vaccination and found that the vaccine was well tolerated. Subjects with chronic HBV infection, chronic HCV infection, and chronic liver disease had seroconversion rates of 94% or greater after two doses of the HAV vaccine, but all of these subjects had lower geometric mean titers as compared with healthy controls.

    Article  PubMed  CAS  Google Scholar 

  24. Tsang SW, Sung JJ: Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 1999, 13:1445–1449.

    Article  PubMed  CAS  Google Scholar 

  25. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB: Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001, 34:28–31. This important study highlights the need for early vaccination in patients with chronic liver disease.

    Article  PubMed  CAS  Google Scholar 

  26. Smallwood GA, Coloura CT, Martinez E, et al.: Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc 2002, 34:3289–3290.

    Article  PubMed  CAS  Google Scholar 

  27. Arslan M, Wiesner RH, Poterucha JJ, Zein NN: Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001, 72:272–276.

    Article  PubMed  CAS  Google Scholar 

  28. Syed NA, Hearing SD, Shaw IS, et al.: Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur J Gastroenterol Hepatol 2003, 15:901–906.

    Article  PubMed  Google Scholar 

  29. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA: The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002, 97:721–728.

    Article  PubMed  Google Scholar 

  30. Myers RP, Gregor JC, Marotta PJ: The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000, 31:834–839.

    Article  PubMed  CAS  Google Scholar 

  31. Jacobs RJ, Meyerhoff AS, Saab S: Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Dig Dis Sci 2005, 50:1525–1531.

    Article  PubMed  Google Scholar 

  32. Chaudhari S, Tenner CT, Weinshel EH, Bini EJ: National survey of physician knowledge and attitudes regarding vaccination against hepatitis A and B in patients with chronic liver disease due to hepatitis C virus infection [abstract]. Gastroenterology 2005, 128:A555-A556.

    Google Scholar 

  33. Chaudhari S, Tenner CT, Weinshel EH, Bini EJ: Barriers to vaccination against hepatitis A and hepatitis B in patients with chronic hepatitis C virus infection: a national survey of U.S. physicians [abstract]. Gastroenterology 2005, 127:A771.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, VA New York Harbor Healthcare System, 423 East 23rd Street, 10010, New York, NY, USA

    Irphan Gaslightwala MD & Edmund J. Bini MD, MPH

Authors
  1. Irphan Gaslightwala MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edmund J. Bini MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edmund J. Bini MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaslightwala, I., Bini, E.J. Vaccination against hepatitis a in patients with chronic liver disease. Curr hepatitis rep 5, 49–53 (2006). https://doi.org/10.1007/s11901-006-0003-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-006-0003-2

Keywords

Search

Navigation